Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

Eli Lilly & Co., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Short-term borrowings and current maturities of long-term debt 3.01 7.90 3.82 4.13 5.35 6.20 2.58 2.25 7.20 5.19 8.24 8.23 5.97 6.94 4.99 1.71 1.77 1.87 0.02 0.03 0.03 2.26
Accounts payable 2.97 2.94 3.58 2.94 3.10 3.07 3.22 2.87 3.11 2.86 3.14 2.79 3.07 3.24 3.48 3.09 3.31 3.32 3.76 3.25 3.20 3.31
Employee compensation 1.61 1.38 2.33 1.86 1.52 1.35 2.40 1.92 1.68 1.33 2.22 1.91 1.63 1.51 2.31 1.96 1.71 1.58 2.72 2.29 1.87 1.45
Sales rebates and discounts 12.59 11.44 12.56 13.93 12.91 11.72 11.44 11.49 11.20 9.80 9.93 10.07 9.84 9.83 10.09 9.44 8.50 7.50 7.20 7.00 6.46 5.68
Dividends payable 0.00 0.00 1.71 0.00 1.54 0.00 1.48 0.00 1.36 0.00 1.31 0.00 1.34 0.00 1.41 0.00 1.47 0.00 1.52 0.00 1.47 0.00
Income taxes payable 3.48 1.62 0.41 0.48 0.58 1.29 0.92 0.92 1.10 1.56 1.18 0.96 0.58 0.32 0.31 0.49 0.24 0.33 1.01 1.93 0.00 0.00
Deferred income taxes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.60 2.53 3.64
Other current liabilities 4.91 5.39 5.57 5.25 5.66 5.93 5.04 4.81 5.17 5.29 6.30 5.49 5.16 5.93 5.72 5.32 6.03 6.56 6.92 5.78 7.29 7.06
Current liabilities 28.57% 30.68% 29.97% 28.58% 30.66% 29.56% 27.07% 24.26% 30.82% 26.03% 32.32% 29.45% 27.58% 27.77% 28.31% 22.01% 23.03% 21.16% 23.14% 22.87% 22.84% 23.40%
Long-term debt, excluding current maturities 35.90 34.02 35.17 36.05 35.48 35.81 26.51 26.16 21.65 21.18 22.10 23.08 24.10 20.30 21.56 23.16 23.81 21.55 22.41 22.23 22.17 20.80
Accrued retirement benefits 8.10 8.84 9.41 6.37 7.04 7.26 6.63 6.02 8.07 7.90 7.81 5.72 6.02 6.53 6.32 5.53 5.54 6.07 6.07 6.50 7.30 7.07
Long-term income taxes payable 8.05 8.81 9.18 9.31 9.01 9.89 8.48 8.38 8.28 8.45 8.40 1.65 1.72 1.85 1.78 2.14 2.21 2.62 2.44 2.51 2.85 2.68
Deferred tax liabilities 4.86 5.32 5.57 6.37 6.16 6.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other noncurrent liabilities 4.35 4.56 3.82 4.18 4.26 4.41 6.46 3.47 3.74 3.55 3.44 5.32 5.97 6.07 5.74 5.62 5.23 5.27 4.91 3.92 4.04 4.14
Other liabilities 61.25% 61.54% 63.16% 62.29% 61.95% 63.69% 48.08% 44.03% 41.75% 41.08% 41.74% 35.77% 37.81% 34.75% 35.40% 36.45% 36.79% 35.52% 35.84% 35.15% 36.35% 34.68%
Total liabilities 89.82% 92.22% 93.13% 90.86% 92.61% 93.25% 75.15% 68.29% 72.57% 67.11% 74.06% 65.22% 65.39% 62.51% 63.72% 58.46% 59.82% 56.68% 58.98% 58.02% 59.19% 58.08%
Common stock 1.43 1.46 1.52 1.58 1.56 1.60 1.51 1.49 1.59 1.53 1.53 1.60 1.68 1.83 1.77 1.84 1.89 1.99 1.94 1.91 1.92 1.95
Additional paid-in capital 15.80 15.95 17.02 17.44 16.90 15.15 14.99 14.62 13.75 12.98 12.93 13.38 13.89 14.93 14.54 15.03 15.32 15.92 15.61 14.99 14.90 14.81
Retained earnings 15.77 14.30 12.52 13.15 11.17 12.84 25.95 32.29 33.63 37.44 30.89 37.54 38.07 42.20 41.35 44.16 43.38 46.57 45.02 46.43 44.72 46.86
Employee benefit trust -7.18 -7.33 -7.67 -7.95 -7.79 -7.93 -6.86 -6.75 -7.11 -6.79 -6.70 -7.01 -7.36 -8.01 -7.76 -8.02 -8.26 -8.69 -8.47 -8.30 -8.36 -8.45
Accumulated other comprehensive loss -15.92 -16.75 -16.61 -15.13 -14.48 -14.96 -13.05 -12.19 -14.42 -12.26 -12.71 -10.72 -11.66 -13.46 -13.59 -11.33 -11.98 -12.29 -12.88 -12.86 -12.22 -13.06
Cost of common stock in treasury -0.13 -0.14 -0.15 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.17 -0.18 -0.19 -0.20 -0.21 -0.21 -0.22 -0.23 -0.25 -0.25 -0.25 -0.25
Total Eli Lilly and Company shareholders’ equity 9.75% 7.49% 6.64% 8.93% 7.19% 6.53% 22.38% 29.30% 27.28% 32.75% 25.77% 34.62% 34.44% 37.29% 36.10% 41.47% 40.13% 43.27% 40.97% 41.93% 40.71% 41.85%
Noncontrolling interests 0.43 0.29 0.23 0.21 0.20 0.22 2.46 2.41 0.15 0.14 0.17 0.16 0.17 0.19 0.19 0.07 0.05 0.06 0.05 0.05 0.10 0.07
Total equity 10.18% 7.78% 6.87% 9.14% 7.39% 6.75% 24.85% 31.71% 27.43% 32.89% 25.94% 34.78% 34.61% 37.49% 36.28% 41.54% 40.18% 43.32% 41.02% 41.98% 40.81% 41.92%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Eli Lilly & Co.’s current liabilities as a percentage of total liabilities and equity increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.
Other liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Eli Lilly & Co.’s other liabilities as a percentage of total liabilities and equity decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Eli Lilly & Co.’s total liabilities as a percentage of total liabilities and equity decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Total Eli Lilly and Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Eli Lilly & Co.’s total Eli Lilly and Company shareholders’ equity as a percentage of total liabilities and equity increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.